ME Therapeutics Holdings Inc. (CSE:METX)

ME Therapeutics Holdings Income Statement

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	May 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022
Selling, General & Admin	0.51	0.37	0.36	0.08
Research & Development	0.29	0.31	0.03	0.05
Operating Expenses	1.2	1.37	0.98	0.15
Operating Income	-1.2	-1.37	-0.98	-0.15
Interest Expense	-0.01	-	-0.01	-0.01
Interest & Investment Income	0.04	0.03	0.01	-
Other Non Operating Income (Expenses)	-	0.05	-	0.02
EBT Excluding Unusual Items	-1.17	-1.29	-0.97	-0.15
Other Unusual Items	-	-	-5.55	-
Pretax Income	-1.17	-1.29	-6.52	-0.15
Net Income	-1.17	-1.29	-6.52	-0.15
Net Income to Common	-1.17	-1.29	-6.52	-0.15
Shares Outstanding (Basic)	27	24	16	8
Shares Outstanding (Diluted)	27	24	16	8
Shares Change (YoY)	21.58%	55.90%	84.08%	-
EPS (Basic)	-0.04	-0.05	-0.42	-0.02
EPS (Diluted)	-0.04	-0.05	-0.42	-0.02
EBITDA	-1.18	-1.37	-0.98	-0.15
D&A For EBITDA	0.02	0	0	0
EBIT	-1.2	-1.37	-0.98	-0.15

Updated Jan 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.